REGULATORY
CSIMC’s Bill Payer, Industry Reps at Odds over Objective of Premium; “Elimination of Drug Lag” vs. “New Drug Development”
A meeting of the Central Social Insurance Medical Council’s (CSIMC) drug pricing subcommittee on October 16 shed renewed light on the discordance between medical bill payers and the pharmaceutical industry over the original goal of the trial introduction of the…
To read the full story
Related Article
REGULATORY
- LDP Lawmakers’ League Urges Continued Coverage for Local Transdermal Analgesics
December 10, 2025
- Senior LDP Lawmakers Call for “Net Plus” in FY2026 Fee, Drug Price Revisions
December 10, 2025
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- JMA Pushes Back on Incentives Tied to Regional Formularies: Chuikyo
December 9, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





